ECSP067079A - Derivados de ácido carboxílico de bencimidazolona - Google Patents

Derivados de ácido carboxílico de bencimidazolona

Info

Publication number
ECSP067079A
ECSP067079A EC2006007079A ECSP067079A ECSP067079A EC SP067079 A ECSP067079 A EC SP067079A EC 2006007079 A EC2006007079 A EC 2006007079A EC SP067079 A ECSP067079 A EC SP067079A EC SP067079 A ECSP067079 A EC SP067079A
Authority
EC
Ecuador
Prior art keywords
disease
compounds
dyspepsia
bencimidazolona
acid derivatives
Prior art date
Application number
EC2006007079A
Other languages
English (en)
Inventor
Satoru Iguchi
Hiroki Sone
Chikara Uchida
Koji Ando
Noriaki Murase
Yoshinori Murata
Toyoharu Numata
Ueki Tatsuo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2004177488A external-priority patent/JP4129445B2/ja
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP067079A publication Critical patent/ECSP067079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a compuestos de fórmula (I): (consta gráfico) en la que R1,R2, R3, A y m son cada uno de ellos como se han descrito en esta memoria descriptiva a una sal o solvato farmacéuticamente aceptable de los mismos, y las composiciones que contienen tales compuestos y el uso de tales compuestos en el tratamiento de una afección mediada por la actividad del receptor 5-HT4 tal como, pero sin limitación a, enfermedad de reflujo gastroesofágico, enfermedad gastrointestinal, trastorno de motilidad gástrica, dispepsia no ulcerosa, dispepsia funcional, síndrome de intestino irritable (IBS), estreñimiento, dispepsia, esofagitis, enfermedad gastroesofágica, nauseas, enfermedad del sistema nervioso central, enfermedad de Alzheimer, trastorno cognitivo, tmesis, migraña, enfermedad neurológico, dolor, trastornos cardiovasculares, tales como insuficiencia cardiaca y arritmia cardiaca, diabetes y síndrome de apnea.
EC2006007079A 2004-06-15 2006-12-13 Derivados de ácido carboxílico de bencimidazolona ECSP067079A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004177488A JP4129445B2 (ja) 2004-06-15 2004-06-15 ベンズイミダゾロンカルボン酸誘導体
US60703504P 2004-09-02 2004-09-02
US60700804P 2004-09-02 2004-09-02
US60704804P 2004-09-02 2004-09-02

Publications (1)

Publication Number Publication Date
ECSP067079A true ECSP067079A (es) 2007-01-26

Family

ID=35414645

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007079A ECSP067079A (es) 2004-06-15 2006-12-13 Derivados de ácido carboxílico de bencimidazolona

Country Status (23)

Country Link
US (3) US7595329B2 (es)
EP (1) EP1758891A2 (es)
KR (1) KR100875558B1 (es)
AR (1) AR049353A1 (es)
AU (1) AU2005254800B2 (es)
BR (1) BRPI0512046A (es)
CA (1) CA2569654C (es)
CR (1) CR8756A (es)
EA (3) EA010891B9 (es)
EC (1) ECSP067079A (es)
GE (1) GEP20094638B (es)
GT (1) GT200500156A (es)
IL (1) IL179612A (es)
MA (1) MA28667B1 (es)
MX (1) MXPA06014486A (es)
NL (1) NL1029250C2 (es)
NO (1) NO20065160L (es)
PA (1) PA8636901A1 (es)
PE (1) PE20060298A1 (es)
SV (1) SV2008002145A (es)
TW (1) TWI298635B (es)
UY (1) UY28961A1 (es)
WO (1) WO2005123718A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
ATE539077T1 (de) * 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
MX2007007818A (es) * 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
ES2523851T3 (es) * 2005-03-02 2014-12-02 Theravance Biopharma R&D Ip, Llc Compuestos de quinolinona como agonistas de los receptores 5-HT4
EP1861377B1 (en) 2005-03-15 2010-12-29 Pfizer, Inc. Benzimidazolone derivatives as cb2 receptor ligands
AU2006262101A1 (en) * 2005-06-23 2007-01-04 Merck & Co., Inc. 3-fluoro-piperidine T-type calcium channel antagonists
AU2006263564A1 (en) * 2005-06-29 2007-01-04 Merck Sharp & Dohme Corp. 4-fluoro-piperidine T-type calcium channel antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
KR20140147142A (ko) * 2006-01-24 2014-12-29 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
RU2569733C2 (ru) 2010-02-12 2015-11-27 Раквалиа Фарма Инк. Агонисты 5-нт4-рецепторов для лечения деменции
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH566987A5 (es) 1972-04-21 1975-09-30 Ciba Geigy Ag
US3945953A (en) 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
JPS5965073A (ja) 1982-10-05 1984-04-13 Kowa Co インド−ル誘導体
DE3336024A1 (de) 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5193547A (en) * 1984-07-16 1993-03-16 Evans Ii George D Universal connector means for transducer/monitor systems
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5552408A (en) * 1987-09-23 1996-09-03 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
IE902465A1 (en) 1989-07-07 1991-02-13 Schering Corp Pharmaceutically active compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9009389D0 (en) 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
JPH06506443A (ja) 1991-01-09 1994-07-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物
US5219850A (en) 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5196547A (en) 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5955470A (en) 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
EP0522914A1 (fr) 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9121170D0 (en) 1991-10-05 1991-11-20 Smithkline Beecham Plc Pharmaceuticals
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) * 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
US5280028A (en) * 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5521193A (en) * 1992-06-24 1996-05-28 G. D. Searle & Co. Benzimidazole compounds
FR2694292B1 (fr) 1992-07-29 1994-10-21 Esteve Labor Dr Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament.
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
GB9221468D0 (en) 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
WO1994010174A1 (en) 1992-11-05 1994-05-11 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
TW251287B (es) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9312348D0 (en) 1993-06-16 1993-07-28 Smithkline Beecham Plc Pharmaceuticals
US5534521A (en) * 1993-06-23 1996-07-09 G. D. Searle & Co. Benzimidazole compounds
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
AU3192295A (en) 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
BR9611311A (pt) 1995-11-09 1999-06-29 Synthelabo Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
JPH10203987A (ja) 1997-01-28 1998-08-04 Dainippon Pharmaceut Co Ltd （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤
FR2762316B1 (fr) 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2303438A1 (en) 1997-09-09 1999-03-18 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
CN1303376A (zh) 1998-03-31 2001-07-11 阿卡蒂亚药品公司 对毒蕈碱性受体具有活性的化合物
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
US6310059B1 (en) * 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
EP1127054A4 (en) * 1998-10-29 2006-11-02 Bristol Myers Squibb Co INHIBITORS OF IMPDH ENZYME
US6420410B1 (en) * 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
WO2001014331A2 (en) 1999-08-24 2001-03-01 Regents Of The University Of California Non-quinoline inhibitors of malaria parasites
JP2003518107A (ja) 1999-12-20 2003-06-03 ニューロメド テクノロジーズ， インコーポレイテッド 部分飽和カルシウムチャネルブロッカー
FR2805815B1 (fr) 2000-03-01 2002-05-17 Sanofi Synthelabo Derives de polyfluoroalkylimidazole, leur preparation et leur application en therapeutique
CN100358892C (zh) * 2000-08-31 2008-01-02 霍夫曼-拉罗奇有限公司 7-氧代吡啶并嘧啶
WO2002030886A2 (en) 2000-10-12 2002-04-18 Matthews Barry R Heterocyclic angiogenesis inhibitors
WO2002046172A2 (en) * 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002053568A1 (en) 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
BR0314584A (pt) 2002-09-20 2005-08-09 Pfizer Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
ITMI20030287A1 (it) * 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
EP1637521B1 (en) 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Novel tricyclic heterocycle compound
ATE539077T1 (de) 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico

Also Published As

Publication number Publication date
US7705020B2 (en) 2010-04-27
US20050277671A1 (en) 2005-12-15
US7595329B2 (en) 2009-09-29
CR8756A (es) 2006-12-13
EA010891B9 (ru) 2012-08-30
KR20070023736A (ko) 2007-02-28
NL1029250A1 (nl) 2005-12-19
TWI298635B (en) 2008-07-11
CA2569654C (en) 2010-12-21
EP1758891A2 (en) 2007-03-07
NL1029250C2 (nl) 2006-06-27
TW200603796A (en) 2006-02-01
US20080108660A1 (en) 2008-05-08
WO2005123718A3 (en) 2006-05-04
BRPI0512046A (pt) 2008-02-06
CA2569654A1 (en) 2005-12-29
EA200602122A1 (ru) 2007-04-27
AR049353A1 (es) 2006-07-19
AU2005254800B2 (en) 2010-12-09
EA200801607A1 (ru) 2008-10-30
UY28961A1 (es) 2006-01-31
EA200801608A1 (ru) 2008-10-30
MA28667B1 (fr) 2007-06-01
AU2005254800A1 (en) 2005-12-29
US20050277673A1 (en) 2005-12-15
KR100875558B1 (ko) 2008-12-23
PE20060298A1 (es) 2006-04-13
SV2008002145A (es) 2008-04-03
WO2005123718A2 (en) 2005-12-29
GEP20094638B (en) 2009-03-10
MXPA06014486A (es) 2007-03-01
IL179612A (en) 2012-06-28
HK1104031A1 (en) 2008-01-04
GT200500156A (es) 2006-01-10
NO20065160L (no) 2006-12-11
IL179612A0 (en) 2007-05-15
PA8636901A1 (es) 2006-08-03
EA010891B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
ECSP067079A (es) Derivados de ácido carboxílico de bencimidazolona
DOP2006000046A (es) Derivados de oxindol
UY29421A1 (es) Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones.
UY28496A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
AU2014219855B2 (en) Trk-inhibiting compound
RU2395506C2 (ru) Антагонисты рецептора хемокина
ES2328630T3 (es) Derivados de 5-amino-4-hydroxi-7-(imidazo (1,2-a>)piridin-6- ilmetil-8-metil-nonamida y compuestos relacionados como inhibidores de la renina para el tratamiento de la hipertension.
JPWO2005047286A1 (ja) スピロ複素環化合物
TW201249796A (en) Heterocyclic modulators of lipid synthesis
KR20140025375A (ko) 지질 합성의 헤테로사이클릭 조절자
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2004035581A1 (ja) スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
DE602006010563D1 (de) Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
JP2009502770A5 (es)
PE20090115A1 (es) Derivados de indol-2-il-piperazin-1-il-metanona
DOP2005000113A (es) Drivados de acido carboxilico de bencimidazolona
WO2015101265A1 (zh) 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
NO20063562L (no) Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
CU20070183A7 (es) Derivados de oxindol
TH76314A (th) สารอนุพันธ์แบบซิมิดาโซโลน คาร์บอกซิลิก แอซิด
DOP2004000986A (es) Compuestos de bencimidazolona que tienen actividad del receptor 5ht-4
TH106943A (th) สารประกอบเบนซิมิดาโซโลนที่มีแอคทิวิทีต่อต้าน 5-ht4 รีเซพเตอร์